Colorectal cancer detection using targeted serum metabolic profiling

Jiangjiang Zhu, Danijel Djukovic, Lingli Deng, Haiwei Gu, Farhan Himmati, E. Gabriela Chiorean, Daniel Raftery

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers in the world. Despite an expanding knowledge of its molecular pathogenesis during the past two decades, robust biomarkers to enable screening, surveillance, and therapy monitoring of CRC are still lacking. In this study, we present a targeted liquid chromatography-tandem mass spectrometry-based metabolic profiling approach for identifying biomarker candidates that could enable highly sensitive and specific CRC detection using human serum samples. In this targeted approach, 158 metabolites from 25 metabolic pathways of potential significance were monitored in 234 serum samples from three groups of patients (66 CRC patients, 76 polyp patients, and 92 healthy controls). Partial least-squares-discriminant analysis (PLS-DA) models were established, which proved to be powerful for distinguishing CRC patients from both healthy controls and polyp patients. Receiver operating characteristic curves generated based on these PLS-DA models showed high sensitivities (0.96 and 0.89, respectively, for differentiating CRC patients from healthy controls or polyp patients), good specificities (0.80 and 0.88), and excellent areas under the curve (0.93 and 0.95). Monte Carlo cross validation was also applied, demonstrating the robust diagnostic power of this metabolic profiling approach.

Original languageEnglish (US)
Pages (from-to)4120-4130
Number of pages11
JournalJournal of Proteome Research
Volume13
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Biomarkers
Discriminant analysis
Serum
Polyps
Liquid chromatography
Metabolites
Discriminant Analysis
Mass spectrometry
Least-Squares Analysis
Screening
Monitoring
Tandem Mass Spectrometry
Metabolic Networks and Pathways
ROC Curve
Liquid Chromatography
Area Under Curve
Neoplasms

Keywords

  • colorectal cancer
  • diagnostic biomarkers
  • LC-MS/MS
  • metabolomics
  • polyps
  • serum metabolites
  • targeted metabolic profiling

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Zhu, J., Djukovic, D., Deng, L., Gu, H., Himmati, F., Chiorean, E. G., & Raftery, D. (2014). Colorectal cancer detection using targeted serum metabolic profiling. Journal of Proteome Research, 13(9), 4120-4130. https://doi.org/10.1021/pr500494u

Colorectal cancer detection using targeted serum metabolic profiling. / Zhu, Jiangjiang; Djukovic, Danijel; Deng, Lingli; Gu, Haiwei; Himmati, Farhan; Chiorean, E. Gabriela; Raftery, Daniel.

In: Journal of Proteome Research, Vol. 13, No. 9, 01.01.2014, p. 4120-4130.

Research output: Contribution to journalArticle

Zhu, J, Djukovic, D, Deng, L, Gu, H, Himmati, F, Chiorean, EG & Raftery, D 2014, 'Colorectal cancer detection using targeted serum metabolic profiling', Journal of Proteome Research, vol. 13, no. 9, pp. 4120-4130. https://doi.org/10.1021/pr500494u
Zhu, Jiangjiang ; Djukovic, Danijel ; Deng, Lingli ; Gu, Haiwei ; Himmati, Farhan ; Chiorean, E. Gabriela ; Raftery, Daniel. / Colorectal cancer detection using targeted serum metabolic profiling. In: Journal of Proteome Research. 2014 ; Vol. 13, No. 9. pp. 4120-4130.
@article{0422a1947aae4880b446038fbff23fcd,
title = "Colorectal cancer detection using targeted serum metabolic profiling",
abstract = "Colorectal cancer (CRC) is one of the most prevalent and deadly cancers in the world. Despite an expanding knowledge of its molecular pathogenesis during the past two decades, robust biomarkers to enable screening, surveillance, and therapy monitoring of CRC are still lacking. In this study, we present a targeted liquid chromatography-tandem mass spectrometry-based metabolic profiling approach for identifying biomarker candidates that could enable highly sensitive and specific CRC detection using human serum samples. In this targeted approach, 158 metabolites from 25 metabolic pathways of potential significance were monitored in 234 serum samples from three groups of patients (66 CRC patients, 76 polyp patients, and 92 healthy controls). Partial least-squares-discriminant analysis (PLS-DA) models were established, which proved to be powerful for distinguishing CRC patients from both healthy controls and polyp patients. Receiver operating characteristic curves generated based on these PLS-DA models showed high sensitivities (0.96 and 0.89, respectively, for differentiating CRC patients from healthy controls or polyp patients), good specificities (0.80 and 0.88), and excellent areas under the curve (0.93 and 0.95). Monte Carlo cross validation was also applied, demonstrating the robust diagnostic power of this metabolic profiling approach.",
keywords = "colorectal cancer, diagnostic biomarkers, LC-MS/MS, metabolomics, polyps, serum metabolites, targeted metabolic profiling",
author = "Jiangjiang Zhu and Danijel Djukovic and Lingli Deng and Haiwei Gu and Farhan Himmati and Chiorean, {E. Gabriela} and Daniel Raftery",
year = "2014",
month = "1",
day = "1",
doi = "10.1021/pr500494u",
language = "English (US)",
volume = "13",
pages = "4120--4130",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Colorectal cancer detection using targeted serum metabolic profiling

AU - Zhu, Jiangjiang

AU - Djukovic, Danijel

AU - Deng, Lingli

AU - Gu, Haiwei

AU - Himmati, Farhan

AU - Chiorean, E. Gabriela

AU - Raftery, Daniel

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Colorectal cancer (CRC) is one of the most prevalent and deadly cancers in the world. Despite an expanding knowledge of its molecular pathogenesis during the past two decades, robust biomarkers to enable screening, surveillance, and therapy monitoring of CRC are still lacking. In this study, we present a targeted liquid chromatography-tandem mass spectrometry-based metabolic profiling approach for identifying biomarker candidates that could enable highly sensitive and specific CRC detection using human serum samples. In this targeted approach, 158 metabolites from 25 metabolic pathways of potential significance were monitored in 234 serum samples from three groups of patients (66 CRC patients, 76 polyp patients, and 92 healthy controls). Partial least-squares-discriminant analysis (PLS-DA) models were established, which proved to be powerful for distinguishing CRC patients from both healthy controls and polyp patients. Receiver operating characteristic curves generated based on these PLS-DA models showed high sensitivities (0.96 and 0.89, respectively, for differentiating CRC patients from healthy controls or polyp patients), good specificities (0.80 and 0.88), and excellent areas under the curve (0.93 and 0.95). Monte Carlo cross validation was also applied, demonstrating the robust diagnostic power of this metabolic profiling approach.

AB - Colorectal cancer (CRC) is one of the most prevalent and deadly cancers in the world. Despite an expanding knowledge of its molecular pathogenesis during the past two decades, robust biomarkers to enable screening, surveillance, and therapy monitoring of CRC are still lacking. In this study, we present a targeted liquid chromatography-tandem mass spectrometry-based metabolic profiling approach for identifying biomarker candidates that could enable highly sensitive and specific CRC detection using human serum samples. In this targeted approach, 158 metabolites from 25 metabolic pathways of potential significance were monitored in 234 serum samples from three groups of patients (66 CRC patients, 76 polyp patients, and 92 healthy controls). Partial least-squares-discriminant analysis (PLS-DA) models were established, which proved to be powerful for distinguishing CRC patients from both healthy controls and polyp patients. Receiver operating characteristic curves generated based on these PLS-DA models showed high sensitivities (0.96 and 0.89, respectively, for differentiating CRC patients from healthy controls or polyp patients), good specificities (0.80 and 0.88), and excellent areas under the curve (0.93 and 0.95). Monte Carlo cross validation was also applied, demonstrating the robust diagnostic power of this metabolic profiling approach.

KW - colorectal cancer

KW - diagnostic biomarkers

KW - LC-MS/MS

KW - metabolomics

KW - polyps

KW - serum metabolites

KW - targeted metabolic profiling

UR - http://www.scopus.com/inward/record.url?scp=84914170537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914170537&partnerID=8YFLogxK

U2 - 10.1021/pr500494u

DO - 10.1021/pr500494u

M3 - Article

C2 - 25126899

AN - SCOPUS:84914170537

VL - 13

SP - 4120

EP - 4130

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 9

ER -